Michael Yee
Stock Analyst at UBS
(3.90)
# 613
Out of 5,157 analysts
108
Total ratings
46.15%
Success rate
12.56%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVB Nuvation Bio | Maintains: Neutral | $10 → $7 | $4.69 | +49.25% | 5 | Mar 3, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $100 → $115 | $114.39 | +0.53% | 2 | Feb 24, 2026 | |
| ABBV AbbVie | Maintains: Neutral | $240 → $230 | $227.01 | +1.32% | 2 | Feb 5, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $535 → $545 | $499.17 | +9.18% | 6 | Jan 26, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $145 → $155 | $148.56 | +4.33% | 5 | Jan 26, 2026 | |
| AMGN Amgen | Maintains: Buy | $380 → $390 | $375.43 | +3.88% | 7 | Jan 26, 2026 | |
| IDYA IDEAYA Biosciences | Assumes: Buy | $50 | $34.74 | +43.93% | 1 | Jan 7, 2026 | |
| DNLI Denali Therapeutics | Assumes: Buy | $25 | $21.43 | +16.66% | 3 | Jan 7, 2026 | |
| IMCR Immunocore Holdings | Assumes: Buy | $24 → $55 | $33.34 | +64.97% | 2 | Jan 7, 2026 | |
| IVA Inventiva | Assumes: Buy | $3 → $12 | $6.58 | +82.37% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 → $70 | $62.01 | +12.89% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $29.19 | +71.29% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $44.78 | +33.99% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $12.63 | +42.52% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $4.10 | +70.73% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $33.69 | +48.41% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $15.76 | +185.53% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $29.01 | +106.83% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $25.11 | +99.12% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $26.08 | +7.36% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.71 | +195.20% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $19.46 | +79.86% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.10 | +181.69% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $46 → $65 | $60.13 | +8.10% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $130 → $185 | $188.41 | -1.81% | 6 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $25 | $27.16 | -7.95% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $1,080 → $1,250 | $1,001.35 | +24.83% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $3 | $2.04 | +47.06% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $55 | $54.98 | +0.04% | 8 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $529.97 | -27.35% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $5.62 | -46.62% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $15.97 | +25.27% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $2.70 | +1,011.11% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $9.77 | +207.06% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $29.60 | +305.41% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $71.63 | -58.12% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $19.45 | +295.89% | 2 | Nov 8, 2018 |
Nuvation Bio
Mar 3, 2026
Maintains: Neutral
Price Target: $10 → $7
Current: $4.69
Upside: +49.25%
Arcellx
Feb 24, 2026
Downgrades: Neutral
Price Target: $100 → $115
Current: $114.39
Upside: +0.53%
AbbVie
Feb 5, 2026
Maintains: Neutral
Price Target: $240 → $230
Current: $227.01
Upside: +1.32%
Vertex Pharmaceuticals
Jan 26, 2026
Maintains: Buy
Price Target: $535 → $545
Current: $499.17
Upside: +9.18%
Gilead Sciences
Jan 26, 2026
Maintains: Buy
Price Target: $145 → $155
Current: $148.56
Upside: +4.33%
Amgen
Jan 26, 2026
Maintains: Buy
Price Target: $380 → $390
Current: $375.43
Upside: +3.88%
IDEAYA Biosciences
Jan 7, 2026
Assumes: Buy
Price Target: $50
Current: $34.74
Upside: +43.93%
Denali Therapeutics
Jan 7, 2026
Assumes: Buy
Price Target: $25
Current: $21.43
Upside: +16.66%
Immunocore Holdings
Jan 7, 2026
Assumes: Buy
Price Target: $24 → $55
Current: $33.34
Upside: +64.97%
Inventiva
Jan 7, 2026
Assumes: Buy
Price Target: $3 → $12
Current: $6.58
Upside: +82.37%
Jan 7, 2026
Assumes: Buy
Price Target: $20 → $70
Current: $62.01
Upside: +12.89%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $29.19
Upside: +71.29%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $44.78
Upside: +33.99%
Jan 7, 2026
Initiates: Neutral
Price Target: $18
Current: $12.63
Upside: +42.52%
Jan 7, 2026
Initiates: Buy
Price Target: $7
Current: $4.10
Upside: +70.73%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $33.69
Upside: +48.41%
Jan 7, 2026
Initiates: Buy
Price Target: $45
Current: $15.76
Upside: +185.53%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $29.01
Upside: +106.83%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $25.11
Upside: +99.12%
Jan 7, 2026
Initiates: Neutral
Price Target: $28
Current: $26.08
Upside: +7.36%
Jan 7, 2026
Initiates: Buy
Price Target: $8
Current: $2.71
Upside: +195.20%
Jan 7, 2026
Initiates: Buy
Price Target: $35
Current: $19.46
Upside: +79.86%
Jan 7, 2026
Initiates: Buy
Price Target: $20
Current: $7.10
Upside: +181.69%
Jan 7, 2026
Upgrades: Buy
Price Target: $46 → $65
Current: $60.13
Upside: +8.10%
Jan 7, 2026
Assumes: Neutral
Price Target: $130 → $185
Current: $188.41
Upside: -1.81%
Jan 7, 2026
Assumes: Neutral
Price Target: $25
Current: $27.16
Upside: -7.95%
Jan 7, 2026
Assumes: Buy
Price Target: $1,080 → $1,250
Current: $1,001.35
Upside: +24.83%
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $2.04
Upside: +47.06%
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $54.98
Upside: +0.04%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $529.97
Upside: -27.35%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $5.62
Upside: -46.62%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $15.97
Upside: +25.27%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $2.70
Upside: +1,011.11%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $9.77
Upside: +207.06%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $29.60
Upside: +305.41%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $71.63
Upside: -58.12%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $19.45
Upside: +295.89%